Malignant neoplasm of trigone of bladder
ICD-10 C67.0 is a billable code used to indicate a diagnosis of malignant neoplasm of trigone of bladder.
C67.0 refers to a malignant neoplasm located specifically at the trigone of the bladder, which is the triangular area at the base of the bladder where the ureters enter and the urethra exits. This type of cancer is part of a broader category of urinary tract malignancies, which can include cancers of the bladder, ureters, and kidneys. The trigone is a critical area due to its role in urinary function and its proximity to other vital structures. Symptoms may include hematuria (blood in urine), dysuria (painful urination), and increased urinary frequency. Diagnosis typically involves imaging studies such as CT scans, cystoscopy, and biopsy to confirm malignancy. Staging of bladder cancer is crucial for determining the appropriate treatment plan and involves assessing the depth of invasion into the bladder wall and the presence of metastasis. Surgical management may include transurethral resection of the bladder tumor (TURBT) for superficial tumors or radical cystectomy for invasive cancers, often accompanied by urinary diversion procedures. The prognosis and treatment options depend significantly on the stage at diagnosis.
Detailed surgical notes, pathology reports, imaging studies, and follow-up care documentation.
Diagnosis and management of bladder tumors, staging assessments, and surgical interventions.
Ensure accurate coding of tumor stage and type, as well as any associated procedures.
Comprehensive treatment plans, chemotherapy regimens, and response assessments.
Management of advanced bladder cancer, including chemotherapy and palliative care.
Documentation of tumor markers and response to treatment is critical for accurate coding.
Used for diagnosis of bladder tumors.
Cystoscopy report and biopsy results.
Urology specialists must document findings accurately.
Performed for invasive bladder cancer.
Operative report detailing the procedure and findings.
Oncology specialists should document staging and treatment plans.
Common symptoms include hematuria, dysuria, and increased urinary frequency. Patients may also experience pelvic pain or urinary retention.
Staging is determined using the TNM system, which assesses tumor size, lymph node involvement, and the presence of metastasis.
